Which of the following patient populations may benefit from anticholinergic agents?

Question

Quizplus · Accepted Answer

Anticholinergic (antimuscarinic)agents such as ipratropium do not have a labeled indication for asthma in the United States.Current asthma guidelines state that ipratropium may have some additive benefit when given with inhaled $\beta$ agonists.Antimuscarinic bronchodilators are not clearly superior to$\beta$ -adrenergic agents in treating asthma.Antimuscarinic and $\beta$-adrenergic agents have an approximately equal effect on flow rates in many patients.These agents may be especially useful in the following asthmatic patients: patients with nocturnal asthma,in which the slightly longer duration of action may protect against nocturnal deterioration of flow rates;patients with psychogenic asthma,which may be mediated through vagal parasympathetic fibers;asthmatic patients with glaucoma,angina,or hypertension who require treatment with $\beta$-blocking agents;patients with notable side effects from theophylline as an alternative to theophylline;and patients with acute,severe episodes of asthma not responding well to F1F1F1S1?F1F1F10 agonists.

Which of the Following Patient Populations May Benefit from Anticholinergic β\betaβ

Which of the Following Patient Populations May Benefit from Anticholinergic $\beta$